『Daily, Sat 7 Nov: ImunoPharm CAR-T; CSPC CEACAM5; Korea Vanrafia; Huawei CGM; East-West Lite』のカバーアート

Daily, Sat 7 Nov: ImunoPharm CAR-T; CSPC CEACAM5; Korea Vanrafia; Huawei CGM; East-West Lite

Daily, Sat 7 Nov: ImunoPharm CAR-T; CSPC CEACAM5; Korea Vanrafia; Huawei CGM; East-West Lite

無料で聴く

ポッドキャストの詳細を見る
概要
Today on The East-West Bio Brief daily, Basil Lui and Ning cover ImunoPharm's Sai Bo Hua CD19 CAR-T approval (China's tenth, Beijing's first); Bio-Thera's golimumab biosimilar; China-out deals (Boehringer–Sino, Qyuns–Caldera, Hinova–Evommune); CSPC's CEACAM5 ADC Phase 1/2; Korea's Vanrafia and rare-disease insurance fast track; Vivoryon reclaiming China rights; Huawei's Class III CGM; our East-West Lite biotech (~40.5) and medtech (~21.8) indices; and the market mood after October's CSI 300 rout.Full transcript and all sources for this episodeAs always, these are our own voices, AI-cloned so we can bring you this every morning, Tuesday to Sunday. Personal views, not investment advice. Basil holds no positions in any company mentioned.Chapters0:05 Intro and AI-voice disclosure0:59 ImunoPharm CAR-T and China-out callback3:59 Korea Vanrafia and rare-disease fast track5:32 Vivoryon regains China rights6:16 Huawei Class III CGM7:09 East-West Lite biotech and medtech indices9:17 Market mood and one thing to watchKey sources: Yicai: ImunoPharm · Bio-Thera · Sino–Boehringer · Qyuns–Caldera · Hinova–Evommune · Endpoints · CSPC · Vanrafia · Korea fast track · Vivoryon · Huawei CGM · Biotech Benchmark · Medtech Benchmark · CNA marketsWeekly LinkedIn newsletter · Apple · Amazon · YouTube
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません